We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Effects of Light-therapy in Alzheimer's Disease (ALZ-Light)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02686190
Recruitment Status : Completed
First Posted : February 19, 2016
Last Update Posted : March 17, 2016
Information provided by (Responsible Party):
Assistance Publique - Hôpitaux de Paris

Brief Summary:

Background: Management of patients with Alzheimer's disease associated with behavioral disturbances is difficult especially in those with agitation/aggression and insomnia and nighttime behaviors. No treatment has shown any efficacy to control these disturbances and psychotropics drugs, i.e. sedatives and hypnotics have numerous adverse effects.

Objective: Assess the effect of bright light therapy on behavioral disturbances of patients with Alzheimer's disease, especially the effect on agitation/aggression and insomnia and nighttime behaviours.

Study design: Multicenter non pharmacological intervention trial, controlled, randomized, open, two-arm design : control group and intervention group.

Centres : Rehabilitation and long term-care units of 4 geriatric hospital wards.

Patients: 120 patients admitted in geriatric hospital wards (30 by centre), with probable Alzheimer's disease according to DSM-IV diagnosis criteria and agitation/aggression (associated or not with insomnia or nighttime behaviors) according to the Neuropsychiatric inventory, nurse scale (NPI-nurse).

Treatments: Intervention group: patients will participate in a program of bright light therapy realised during a one-hour sessions of occupational therapy,. These sessions will be realised for groups of 6 patients and will be done every week day, at late morning, for 4 consecutive weeks). During the session, patients will be exposed to 10000 lux-bright light. Patients of control group will participate in a program of occupational therapy of same duration and rhythm, realised in standard light conditions (about 300 lux).

Assessment: Patients with be assessed on 3 occasions: inclusion, two and four weeks after the beginning of the programs. Assessment will comprise ; NPI-nurse scale and Cohen-Mansfield scale for behaviour disturbances, wrist actimetry for sleep and nighttime behaviours (total sleep length, nocturnal wake episodes and nocturnal motor agitation).

Judgment criteria: Principal: changes in the agitation/aggression item of NPI-nurse scale. Secondary: changes of the nightime behaviours item of NPI-nurse scale, the Cohen-Mansfield, total sleep duration and numbers of nocturnal wake episodes measured by wrist actimetry.

Statistics: Changes in agitation/aggression scores od the two groups will be compared by Mann and Whitney test.

Expected results and perspectives; If bright light exposure is efficient, professional caregivers of Alzheimer's disease patients might apply this cheap and non pharmacological approach to improve behaviour and sleep of these patients. This study might contribute to better define the place of a non invasive and promising technique, wrist actigraphy, to assess sleep and behaviour disturbances in psychogeriatric patients

Condition or disease Intervention/treatment
Alzheimer's Disease Other: Luxtherapy

  Show Detailed Description

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 91 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Effects of Bright Light to Improve Agitation and Sleep Disorders in Patients With Alzheimer's Disease
Study Start Date : July 2012
Primary Completion Date : April 2014
Study Completion Date : December 2014

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: Luxtherapy
Luxtherapy exposition
Other: Luxtherapy
No Intervention: Not luxtherapy
Not luxtherapy exposition

Primary Outcome Measures :
  1. score agitation / aggression scale NPI-nurse [ Time Frame: Baseline, 2 weeks and 4 weeks ]
    Change over time of the score obtained in item agitation-aggression of the NPI-level nurse.

Secondary Outcome Measures :
  1. score agitation-aggression scale NPI-nurse [ Time Frame: Baseline, 2 weeks and 4 weeks ]
    Change over time score to item nocturnal sleep-behavior of the NPI-nurse

Other Outcome Measures:
  1. scale score Cohen-Mansfield [ Time Frame: Baseline, 2 weeks and 4 weeks ]
    Change over time in the Cohen-Mansfield scale

  2. MMSE scale score [ Time Frame: Baseline and 4 weeks ]
    Change over time score scale MMSE

  3. Nocturnal sleep data measured by wrist actimetry [ Time Frame: Baseline, 2 weeks and 4 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   60 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • Age over 60 years
  • Patient hospitalized in geriatric care immediately or long-term care,
  • Patients with probable Alzheimer's disease according to NINCDS-ADRDA
  • Stage of moderate to severe Alzheimer's disease (defined as MMSE between 2 and 21).
  • Patients with agitation rated 4 or more per item agitation / aggression of the behavior rating scale Neuropsychiatric Inventory-nurse,
  • Patient free from acute disease.
  • Patient with sleep apnea evaluation scale ONSI (Observation-based nocturnal Sleep Inventory) negative
  • Affiliation to a social security scheme
  • Signature of consent by the patient himself or the trusted person or legal representative for patients under guardianship

Exclusion criteria:

  • Patients may leave the ward within 4 weeks
  • Patient refusing to participate in the study
  • Patient with a trusted person and / or legal representative which refuses participation in the study.
  • Patients suffering from retinopathy (DMLA, proliferative diabetic retinopathy) or blindness for whatever reason, lack of crystalline (or aphakia). (These conditions will be systematically sought by an ophthalmologic consultation if the patient has not had in the year before inclusion.)
  • Patient receiving photosensitizing drug imipramine, lithium, tetracycline, hydrochlorothiazide, phenothiazine.
  • Patients suffering from porphyria.
  • Patient with known sleep apnea syndrome. (A specific test for the detection of sleep apnea will be checked prior to the inclusion of patients. This is the test ONSI, validated in elderly demented persons, and allowing screened for sleep apnea in patients with a sensitivity of 91%. ONSI positive test will be an exclusion criteria of the study.)
  • Patient with known REM sleep behavior disorder
  • Patients with clinical criteria of mental confusion as diagnosing clinician.
  • Patient with obvious pathology may itself cause behavior disorders: psychosis, manic-depressive illness, a condition with acute or chronic pain. (In these cases, the inclusion of the patient may be reviewed after returning to a stable clinical condition for at least 3 weeks.)
  • Unbalanced psychotropic treatment subject to dose modifications in the previous 4 weeks (patients receiving one or more psychotropic stable dose for at least 3 weeks may be included).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02686190

Hôpital Charles Foix
Ivry-sur-Seine, France, 94205
Sponsors and Collaborators
Assistance Publique - Hôpitaux de Paris
Principal Investigator: Joël BELMIN, PUPH 00 331 49 59 45 65

Responsible Party: Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier: NCT02686190     History of Changes
Other Study ID Numbers: P081119
IDRCB ( Other Identifier: 2011-A01601-40 )
First Posted: February 19, 2016    Key Record Dates
Last Update Posted: March 17, 2016
Last Verified: February 2016

Keywords provided by Assistance Publique - Hôpitaux de Paris:
Alzheimer; luxtherapy, sleep disturbance, behaviour disturbance

Additional relevant MeSH terms:
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders